Vaccine Development Against Leishmania donovani

Area of Science:

• Parasitology
• Immunology
• Vaccinology

Background:

• Visceral leishmaniasis (VL), caused by Leishmania parasites, is a major global health concern with high mortality.
• Zoonotic VL, transmitted by dogs, poses a significant challenge due to complex transmission cycles and limited control measures.
• Existing treatments for VL are toxic and facing increasing drug resistance, highlighting the urgent need for new strategies.

Purpose of the Study:

• To review the current knowledge on VL pathogenesis and protective immunity.
• To discuss promising vaccine candidates and their developmental status for VL.
• To address challenges and future prospects in developing effective VL vaccines.

Main Methods:

• Literature review of pathogenesis, immune response, and vaccine development in VL.
• Analysis of advances in vaccinology, including novel antigen delivery and prime-boost strategies.
• Discussion of preclinical and clinical trial considerations for VL vaccines.

Main Results:

• Significant progress has been made in understanding VL pathogenesis and immune responses.
• Several promising vaccine candidates utilizing advanced vaccinology approaches are under development.
• Canine VL vaccination is crucial for preventing human infection.

Conclusions:

• Despite challenges, recent advances in vaccinology offer promising avenues for developing effective VL vaccines.
• Further research, preclinical studies, and well-designed clinical trials are essential for successful vaccine development.
• A coordinated effort is needed to overcome hurdles in creating prophylactic strategies against this lethal infection.